• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

    6/10/26 9:16:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYFT alert in real time by email

    ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development.

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows.

    Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs, omics, literature, evidence, provenance, and program history are transformed into a governed, queryable connected biological context for AI-enabled discovery.

    "In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic," said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp.

    LensAI and customer-selected agent models can then retrieve, analyze, and generate hypotheses from connected biological context rather than isolated files.

    HYFT® is MindWalk's core biological pattern technology. It provides the underlying biological representation foundation with explicit relationships across sequence, structure, function, mechanism, pathway, evidence, and literature.

    ReefIQ™ is the client biological context layer built on HYFT. It harmonizes client discovery data, links it to MindWalk's biological representation foundation, preserves provenance and program history, and exposes governed, queryable context to LensAI and customer-selected agent models.

    LensAI™ is the reasoning and application layer. It uses ReefIQ's connected biological context to support retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support.

    HYFT powers the biological representation. ReefIQ organizes and governs the context. LensAI applies reasoning workflows.

    Why this layer matters

    Drug-discovery organizations generate valuable context in every program: positive results, negative results, assay conditions, design decisions, mechanism hypotheses, literature links, and reasons candidates did not advance. ReefIQ preserves that context as governed, queryable knowledge. As data are added, the network is enriched and its relationships and annotations are refined. Future programs benefit from the ever-compounding evidence and insights.

    Inspired by cumulative biological systems

    A reef grows by connecting what came before into a living structure. ReefIQ uses that metaphor for scientific knowledge: each dataset, result, program, and piece of evidence can become part of a governed context layer for future discovery.

    "ReefIQ operationalizes the HYFT information network for drug discovery," said Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk. "HYFT provides the biological representation foundation, representing the complex relationships in biology; ReefIQ links customer data to that foundation and exposes governed context to LensAI and customer-selected agent models operating within agreed governance. The goal is to support retrieval, analysis, and hypothesis generation over connected biological context while preserving provenance, deployment flexibility, and customer-defined controls."

    What comes next

    ReefIQ™ is designed to become the foundation for MindWalk's future life-sciences engagements: a HYFT-powered biological context layer beneath LensAI™ and client-selected model or agent workflows. The architecture supports flexible integration across data governance, model access, and compute deployment. LensAI is already in contracted, recurring arrangements with life-sciences customers today. Interested parties may request a private briefing through Investor Relations.

    For more information about the technology, please visit: https://www.mindwalkai.com/reefiq

    About MindWalk Holdings Corp.

    MindWalk Holdings Corp. (NASDAQ:HYFT) is a bio-native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require. Its proprietary HYFT® system powers ReefIQ™, the biological context layer for life sciences, a function-aware representation organized around HYFT pattern-objects that span sequence and structural biology, refined over 20 years of curation by a continuously evolving Knowledge Graph of 660 million biological patterns and 25 billion relationships, that enriches data at ingestion and compounds in analytical value with every program run on the platform. The LensAI™ platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic AI workflows pharma is racing to deploy. MindWalk's architecture is designed so that the HYFT representation layer, not any individual AI model, is the durable, compounding competitive asset.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by terms such as "expects," "intends," "plans," "anticipates," "believes," "estimates," "targets," or similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding: the launch and branding of ReefIQ, the Company's biological context layer for life sciences, including trademark clearance of the product name; the characterization of ReefIQ as a HYFT-powered biological context layer that sits between client discovery data and AI reasoning workflows, of HYFT as the technology that powers the biological representation, and of LensAI as the reasoning and application layer that operates over that context; the description of an architecture intended to support flexible integration across data governance, model access, and compute deployment in regulated life-sciences workflows; the characterization of the Knowledge Graph's scale (660 million biological patterns and 25 billion relationships) and of ReefIQ enrichment as compounding in analytical value over time; statements regarding contracted, recurring arrangements with life-sciences customers; and the Company's business development objectives.

    Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including: risks relating to the branding, market acceptance, and commercial outcomes of ReefIQ, including trademark availability and clearance for the ReefIQ name; the build-out and certification of compliance capabilities for regulated workloads; the ability to convert engagement into contracted arrangements; the technical performance of AI-based discovery methods and of the underlying compute infrastructure; the ability to enter into pharmaceutical, infrastructure, or other partnership arrangements; competition; intellectual property risks; regulatory determinations; and capital markets conditions. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, MindWalk undertakes no obligation to update any forward-looking statement. Nothing in this press release constitutes investment advice. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

    Trademarks: HYFT® is a registered trademark of MindWalk Holdings Corp. LensAI™, ReefIQ™, HYFT Base™, HYFT Matrix™, HYFT Prime™, and B cell Llama™ are trademarks of MindWalk Holdings Corp. or its subsidiaries.

    Source: MindWalk Holdings Corp.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260610294167/en/

    Investor Relations, Louie Toma, CPA, CFA, Managing Director, CoreIR, investors@mindwalkai.com

    Get the next $HYFT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYFT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYFT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

    6/12/26 9:00:00 AM ET
    $ABSI
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

    ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs

    6/10/26 9:16:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    SEC Filings

    View All

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    6/12/26 9:51:38 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    6/10/26 9:43:59 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by MindWalk Holdings Corp.

    6-K - MindWalk Holdings Corp. (0001715925) (Filer)

    6/2/26 10:32:14 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    Financials

    Live finance-specific insights

    View All

    MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

    Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform MindWalk Holdings Corp. (NASDAQ:HYFT), a Bio-Native AI company focused on biologics discovery and AI-driven drug development, today reported financial results for the third quarter of fiscal year 2026, ended January 31, 2026. MindWalk will host its Q3 Fiscal 2026 Earnings Call today at 10:30 AM Eastern Time. Revenue for Q3 was $4.2 million, a 52 percent increase from $2.7 million in Q3 fiscal 2025, marking MindWalk's third consecutive quarter of year-over-year revenue growth. US revenue doubled year over year to $2.6 million

    3/12/26 8:31:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

    The Company to host an earnings conference call via webcast MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details The live webcast will take place on Thursday, March 12, 2026, at 10:30AM ET. The conference call will be webcast live and availa

    3/2/26 8:31:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

    MindWalk (NASDAQ:HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives. MindWalk operates a proprietary BioNative AI platform built on patented HYFT® patterns—evolution shaped subsequence codes that link sequence, structure and function. These patterns underpin LensAI™, a software platform that harmonizes and analyzes diverse biological data to deliver actionable insights. Financial Highlights (Quarter Ended October 31, 2025) Revenue: $4.1 mi

    12/15/25 8:30:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYFT
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

    6/12/26 9:00:00 AM ET
    $ABSI
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM. The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk's HYFT®-powered LensAi™ platform is unlocking new op

    11/13/25 9:00:00 AM ET
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care